325 related articles for article (PubMed ID: 19281920)
1. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.
Brilakis ES; Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Haagen D; Saeed B; Gadiparthi C; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S
J Am Coll Cardiol; 2009 Mar; 53(11):919-28. PubMed ID: 19281920
[TBL] [Abstract][Full Text] [Related]
2. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial.
Brilakis ES; Lichtenwalter C; Abdel-karim AR; de Lemos JA; Obel O; Addo T; Roesle M; Haagen D; Rangan BV; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S
JACC Cardiovasc Interv; 2011 Feb; 4(2):176-82. PubMed ID: 21349456
[TBL] [Abstract][Full Text] [Related]
3. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial.
Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Holper EM; Haagen D; Saeed B; Iturbe JM; Shunk K; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S; Brilakis ES
JACC Cardiovasc Interv; 2009 Sep; 2(9):855-60. PubMed ID: 19778774
[TBL] [Abstract][Full Text] [Related]
4. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions.
Wöhrle J; Nusser T; Kestler HA; Kochs M; Hombach V
Clin Res Cardiol; 2007 Feb; 96(2):70-6. PubMed ID: 17146605
[TBL] [Abstract][Full Text] [Related]
6. Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study.
Hoffmann R; Pohl T; Köster R; Blindt R; Boeckstegers P; Heitzer T
Heart; 2007 Mar; 93(3):331-4. PubMed ID: 16940392
[TBL] [Abstract][Full Text] [Related]
7. 5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial.
Stone GW; Goldberg S; O'Shaughnessy C; Midei M; Siegel RM; Cristea E; Dangas G; Lansky AJ; Mehran R
JACC Cardiovasc Interv; 2011 Mar; 4(3):300-9. PubMed ID: 21435608
[TBL] [Abstract][Full Text] [Related]
8. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
9. Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: insights from the SOS (Stenting of Saphenous Vein Grafts) trial.
Michael TT; Abdel-karim AR; Papayannis A; Lichtenwalter C; de Lemos JA; Obel O; Addo T; Roesle M; Haagen D; Rangan BV; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger PB; Banerjee S; Brilakis ES
J Invasive Cardiol; 2011 Jun; 23(6):216-9. PubMed ID: 21646644
[TBL] [Abstract][Full Text] [Related]
10. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial.
Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Van den Branden F; Van Langenhove G;
J Am Coll Cardiol; 2007 Jul; 50(3):261-7. PubMed ID: 17631219
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.
Stone GW; Lansky AJ; Pocock SJ; Gersh BJ; Dangas G; Wong SC; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Möckel M; Ochala A; Kellock A; Parise H; Mehran R;
N Engl J Med; 2009 May; 360(19):1946-59. PubMed ID: 19420364
[TBL] [Abstract][Full Text] [Related]
14. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
Di Lorenzo E; Sauro R; Varricchio A; Carbone G; Cortese G; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
Circulation; 2009 Sep; 120(11):964-72. PubMed ID: 19720939
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stents in saphenous vein grafts: intravascular ultrasonography analysis of the SOS (Stenting of Saphenous Vein Grafts) trial.
Jeroudi OM; Abdel-Karim AR; Michael TT; Lichtenwalter C; de Lemos JA; Obel O; Addo T; Roesle M; Haagen D; Rangan BV; Raghunathan D; DaSilva M; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S; Brilakis ES
EuroIntervention; 2011 Dec; 7(8):948-54. PubMed ID: 22157480
[TBL] [Abstract][Full Text] [Related]
16. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
[TBL] [Abstract][Full Text] [Related]
17. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome.
Ge L; Iakovou I; Sangiorgi GM; Chieffo A; Melzi G; Cosgrave J; Montorfano M; Michev I; Airoldi F; Carlino M; Corvaja N; Colombo A
J Am Coll Cardiol; 2005 Apr; 45(7):989-94. PubMed ID: 15808752
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
[TBL] [Abstract][Full Text] [Related]
19. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
